[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635788":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":30,"locations":36,"responsibleParty":51,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":73,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":87,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CHIP-PCI Registry Cohort",null,"Patients with complex high-risk indicated coronary artery disease undergoing percutaneous coronary intervention as part of routine clinical practice. Eligible patients include adults with complex coronary anatomy and reduced left ventricular function who are considered by the heart team to have an indication for coronary revascularization but are at high risk for coronary artery bypass grafting or decline surgical revascularization. PCI strategy, use of intravascular imaging or physiological assessment, revascularization approach, antithrombotic therapy, and use of mechanical circulatory support are determined by the treating physicians according to clinical judgment and local practice. No study-mandated intervention is assigned.",[13,14],"Procedure: Percutaneous Coronary Intervention","Device: Mechanical Circulatory Support",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Percutaneous Coronary Intervention","Percutaneous coronary intervention performed as part of routine clinical care in patients with complex high-risk indicated coronary artery disease. The procedural strategy, use of intravascular imaging or physiological assessment, lesion preparation, revascularization extent, staged PCI, antithrombotic therapy, and use of mechanical circulatory support are determined by the treating physicians according to clinical judgment and local practice. No study-mandated intervention is assigned.",[9],[22],"PCI",{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DEVICE","Mechanical Circulatory Support","Mechanical circulatory support, including intra-aortic balloon pump, extracorporeal membrane oxygenation, Impella-like devices, or other support devices, may be used during high-risk PCI at the discretion of the treating physicians. Use of mechanical circulatory support is not mandated by the study protocol and will be analyzed as an observational exposure.",[9],[29],"MCS",[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Guofeng Gao, MD","CONTACT","+86-13811458815","ggf03@163.com",[37],{"facility":38,"status":10,"city":39,"state":10,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","Beijing","100037","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},{"type":52,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Guofeng Gao","Associate Chief Physician",[56],{"name":57,"class":58},"Shenzhen Core Medical Technology CO.,LTD.","INDUSTRY","100635788","chip-cc-registry-a-prospective-multicenter-registry-of-complex-high-risk-pci-in-china-100635788",false,"NCT07557238","CHIP-CC Registry: A Prospective Multicenter Registry of Complex High-Risk PCI in China","A Prospective, Multicenter, Observational Registry to Evaluate Clinical Outcomes and Prognostic Factors in Patients Undergoing Complex High-Risk Indicated Percutaneous Coronary Intervention in China","CHIP-CC","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Age 18 to 90 years.\n2. Willing and able to comply with the study protocol and data collection procedures, able to understand the purpose of the study, and willing to provide written informed consent.\n3. Considered by the heart team to have an indication for coronary revascularization but to be at high risk for coronary artery bypass grafting, or the patient declines coronary artery bypass grafting, and PCI is considered potentially beneficial after heart team evaluation.\n4. Left ventricular ejection fraction ≤35%, or left ventricular ejection fraction ≤40% with severe mitral regurgitation.\n5. Undergoing complex PCI with at least one of the following features:\n\n   * Unprotected left main coronary artery disease;\n   * PCI of the last remaining patent coronary artery;\n   * Three-vessel coronary artery disease;\n   * Calcified coronary lesion requiring rotational atherectomy;\n   * Chronic total occlusion requiring bilateral angiography or retrograde techniques.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Acute ST-segment elevation myocardial infarction within 1 week before enrollment.\n2. Cardiogenic shock, defined by all of the following:\n\n   * Systolic arterial blood pressure \\\u003C90 mmHg for ≥30 minutes, or need for vasopressors, inotropes, or mechanical circulatory support to maintain systolic arterial blood pressure ≥90 mmHg;\n   * Evidence of reduced cardiac output, such as cardiac index \\\u003C2.2 L\u002Fmin\u002Fm²;\n   * Evidence of end-organ hypoperfusion, including cold extremities, urine output \\\u003C30 mL\u002Fhour, altered mental status, or lactate \\>2 mmol\u002FL.\n3. Unable to complete the planned follow-up.\n4. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the registry.","ALL","18 Years","90 Years",{"count":71,"type":72},1000,"ESTIMATED","2 Years","OBSERVATIONAL","This is a prospective, multicenter, observational registry designed to evaluate clinical outcomes in patients undergoing complex high-risk indicated percutaneous coronary intervention (CHIP-PCI) in China. Eligible patients will be adults with complex coronary artery disease and severely reduced left ventricular function, or reduced left ventricular function with severe mitral regurgitation, who are considered by the heart team to have an indication for coronary revascularization but are at high risk for coronary artery bypass grafting or decline surgical revascularization.\n\nThe registry will collect baseline clinical characteristics, coronary angiographic and procedural data, use of intravascular imaging or physiological assessment, revascularization strategy, mechanical circulatory support, peri-procedural complications, laboratory and echocardiographic data, and follow-up outcomes. The primary endpoint is all-cause mortality at 1 year after PCI. Secondary endpoints include major adverse cardiovascular events, cardiac death, myocardial infarction, target vessel revascularization, heart failure hospitalization, major bleeding, and quality-of-life measures. The study also aims to identify prognostic factors and develop a risk prediction model for patients undergoing CHIP-PCI.",[77,78,79],"Coronary Artery Disease","High Risk PCI","Percutaneous Coronary Intervention (PCI)",[81,82,18,77,83,84,85,86],"CHIP","complex high-risk PCI","left ventricular dysfunction","mechanical circulatory support","clinical outcomes","real-world registry","NOT_YET_RECRUITING","2026-05-07",{"date":90,"type":91},"2026-05-12","ACTUAL",{"date":93,"type":72},"2026-06-01",{"date":95,"type":72},"2029-12-31",{"name":53,"class":6},1]